Abstracts

NEGR1 Genetic Variants and Risk for Virological Failure With Genotypic Resistance in Botswana

Background: Access to antiretroviral therapy (ART) in sub-Saharan Africa has expanded due to a large number of national initiatives. Published findings from the Tshepo study previously demonstrated that NNRTI-assigned ART had no effect on the development of virological failure with genotypic resistance (VF/r) when evaluating persons randomized to receive nevirapine versus efavirenz-based ART. Here, we…

Raltegravir Non-inferior to Standard of Care in SECOND-LINE Therapy Over 96 Weeks

Background: A regimen of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) demonstrated non-inferior efficacy relative to a regimen of LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) in primary analysis at 48 weeks. In this analysis we aim to assess durability of effect over 96 weeks. Methodology: A total of 541 HIV-1 infected adults virologically failing first-line NNRTI+2N(t)RTI…

Partner-Based Intervention for Adherence to Second-line ART: A Multinational Trial (ACTG A5234)

Background: Adherence is a fundamental determinant of antiretroviral therapy (ART) success. Some programs require patients to identify a support partner to enhance adherence. However, evidence supporting this strategy’s effectiveness is lacking. Methodology: We conducted a 1:1 randomized trial of a treatment partner-based intervention compared with usual care for second-line ART at 9 low and middle…

Predictors of Late Virological Failure After Initial Successful Suppression on EFV-based ART

Background: There are practical issues, including high cost, in implementing virologic monitoring of patients on antiretroviral therapy (ART) in resourcelimited settings. We evaluated factors that might guide less frequent virologic monitoring after successful virologic suppression on efavirenz (EFV)-based ART in such settings. Methodology: HIV-1 RNA was measured every 8 weeks in antiretroviral naive participants with…

Mortality among HIV+ Participants Randomized to Omit NRTIs vs. Add NRTIs in OPTIONS (ACTG A5241)

Background: OPTIONS enrolled treatment experienced participants with virologic failure who then started a new regimen after randomization to omit or add NRTIs. In the primary week 48 analysis, we found that omitting NRTIs was not inferior to adding NRTIs (CROI 2013, 153LB). In this analysis, we examined all-cause mortality. Methodology: A5241 enrolled 360 subjects who…

Randomized Comparison of Three Second Line ART Regimens in Africa: the 2 Lady/ANRS/EDCTP Study

Background: Access to antiretroviral therapy (ART) has increased significantly in the last decade: 9.7 million people were on ART at the end of 2012, 2.9% only on second line. WHO recommends the use of a ritonavir boosted Protease Inhibitor (PI/b) containing regimen in patients failing a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-based first line, but evidence…